Loading...
•
Dec 31, 2022
Essa Pharma Q1 2023 Earnings Report
Reported financial results for the fiscal first quarter ended December 31, 2022.
Key Takeaways
ESSA Pharma reported its financial results for the fiscal first quarter ended December 31, 2022. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.
Advanced studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC).
Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) in patients with mCRPC naïve to second generation anti-androgens expected to complete in 1H2023.
Phase 2 randomized study in the same patient population to be initiated shortly thereafter.
Cash runway expected to fund operations and clinical programs through 2025.
Essa Pharma
Essa Pharma
Forward Guidance
The company expects to complete the Phase 1 EPI-7386 combination study with enzalutamide in the first half of 2023 and initiate the Phase 2 randomized study shortly thereafter. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.
Positive Outlook
- Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023.
- Initiation of the randomized Phase 2 study shortly thereafter.
- Ongoing Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients.
- Cash runway expected to fund operations and clinical programs through 2025.
- Advancing studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer.